Nektar Therapeutics (Nasdaq: NKTR) presented promising data from preclinical studies of NKTR-181, a next-generation mu-opioid analgesic candidate with a novel molecular design. NKTR-181 is being developed to effectively treat pain while addressing the abuse liability and serious side effects associated with traditional opioid therapies. The data are being featured in an oral abstract session and poster presentation at the 5th Annual Frontiers of Clinical Investigation Symposium Pain 2010: From Bench to Bedside in La Jolla, CA...
More...
More...